Peramivir Trihydrate is a trihydrate of the anti-infection agent Peramivir Trihydrate which is a transition-state analogue and a potent, specific influenza viral neuraminidase inhibitor with an IC50 of median 0.09 nM.[1] The IC50 for Peramivir Trihydrate
ChEBI: A hydrate that is the trihydrate form of peramivir. Used for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days.
Peramivir trihydrate (0.3125-40 μM, 4 h) has nontoxicity to macrophage.
Peramivir trihydrate (2-10 μM, 6-12 h) inhibits cytokine release in LPS-induced hPBMCs.
Peramivir trihydrate (20-60 mg/kg, i.p., single dose) inhibits LPS-induced cytokine storm, attenuates acute lung injury and prolongs the survival in cytokine storm syndrome model mice.
Peramivir trihydrate (75 mg/kg, i.m., once a day for 7 days) rescued BALB scid mice from lethal challenge with BR/08 in immunocompromised murine models of infuenza B virus infection.
